Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

lasting from three months to up to 20 months, including nine patients with stable disease for more than six months.

Preliminary analyses of pharmacodynamic samples show changes in VEGF-A, sVEGFR2 and PIGF consistent with effects observed with other antiangiogenic agents. Preliminary pharmacokinetic analyses of nine dose levels (0.08-11.52 mg/kg) indicate a long half-life of XL184 of 59 to 136 hours.

"In this study of XL184, we observed partial responses in patients with medullary thyroid cancer and tumor shrinkage in a patient with papillary renal cell cancer, which frequently have mutational activation or overexpression of RET or MET, respectively," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We believe the data to date demonstrate the potential of simultaneous inhibition of MET, RET, and VEGFR, and validate our ability to discover and develop compounds that simultaneously inhibit critical pathways in cancer. We are excited about the potential of XL184 to provide effective therapy for patients with a variety of tumor types, and we intend to advance XL184 into a phase 2 program by the end of 2007."

To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema, Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg, as well as a DLT of Grade 2 mucositis in a patient dosed at 265 mg. Serious adverse events (AEs) considered possibly or probably related to XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary embolism. Dose escalation continues in order to determine a maximum tolerated dose (MTD).

About the Trial

This phase 1, open-label, dose-finding trial is being conducted in patients aged 18 years or older with histologically confirmed advanced solid malignancy or lymphoma that is metastatic or unresectable and for which alternative therapies do not exist or are no longer effective. P
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to ... with LaurelCo, LLC, an Illinois limited ... and dispensary medical marijuana licenses in the state of ... acquire a 20% equity interest in LaurelCo, LLC in exchange ... chambers, as well as all technology related to the machines ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Acsis Addresses Questions on the Modern Supply Chain 2
... 17 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) ... Oxygen Concentrate Gel to customers who have pre-ordered through ... today, cover orders received through early November. , "This ... actually shipping a product to customers and generating revenue ...
... , REYKJAVIK, Iceland, Nov. 17 deCODE ... has filed a voluntary petition for relief under Chapter 11 ... Bankruptcy Court for the District of Delaware to facilitate the ... to operate its business and manage its properties as a ...
Cached Medicine Technology:Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 3deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 4
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
(Date:7/25/2014)... As reported by the New Orleans Advocate ... (7/3), the state of Louisiana has recently seen a ... than cocaine. Officials believe the increase is due to a ... of marijuana. However, both doctors and police confirm that that ... to call it “poison,” doctors have acknowledged that the Louisiana ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... Houston, TX (PRWEB) July 25, 2014 ... Annual Family Fun Fest on Sunday, July 27 at ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, ... location in The Heights. , “We’re thrilled to ... this year,” said Heather Belcher who owns the Sugarland-Missouri ...
(Date:7/25/2014)... July 25, 2014 A new study conducted ... revealed that 39 percent of all children in the survey under ... The survey looked at 2,505 children during the years of 2011 ... years of age. The final result was that about two ... Many of these children were from lower-income families and were of ...
Breaking Medicine News(10 mins):Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... UCSF institute aimed at accelerating the pace of translating ... million from the National Institutes of Health to expand ... UCSF Clinical and Translational Science Institute (CTSI) is among ... recognition of their successes during the first five years ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay News) -- ... of mild cognitive impairment, a potential precursor of Alzheimer,s ... there may be a very high rate of cognitive ... general population in that age range," said lead researcher ...
... , FRIDAY, July 15 (HealthDay News) -- Although many people ... relationship between stress and alcohol is a two-way street, researchers ... stress, the authors of a new study pointed out. Meanwhile, ... individuals to drink more to produce the same effect. As ...
... (HealthDay News) -- Compared with older people with no signs of ... twice as likely to experience a fall, researchers have found. ... older adults who were participating in a study of memory and ... many times they fell over the course of eight months. ...
... 2011) Today at the 6th International AIDS ... Prevention, the Drugs for Neglected Diseases initiative (DNDi) ... programme to address critical unmet treatment needs of ... in young children has largely been eliminated in ...
... York University,s Department of Chemistry and NYU Langone Medical ... a protein implicated in many types of cancer. The ... journal Nature Chemical Biology. The ... RTK signaling is a major underlying cause of various ...
Cached Medicine News:Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 2Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 3Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 4Health News: Drinking Alcohol May Prolong, Not Relieve, Stress 2Health News:Falls Could Signal Early Alzheimer's Disease 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 3
... integrates drug infusion,with patient monitoring and ... modular platform. With multiple configuration,options, you ... you,need them, keeping the number of ... while managing the unique needs of,each ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... the first steps any hospital or health ... most powerful, most effective tools available for ... world-class clinician documentation and electronic medical record ... achieve this goal. In fact, its the ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
Medicine Products: